Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per ...

Illumina Inc. ILMN reported first-quarter 2025 adjusted earnings per share (EPS) of 97 cents, which topped the Zacks Consensus Estimate by 1%. However, the figure was down 1% on a year-over-year ...

research revenue growth and mitigation strategies for China-related risks. CEO Thaysen emphasized resilience in Illumina's core business and measures to fully compensate for potential China ...

Illumina Inc. cut its full-year adjusted profit guidance for the second time in three months as it grapples with the impact of tariffs and China banning imports of its gene-sequencing machines ...

Good day ladies and gentlemen, and welcome to the First Quarter 2025 Illumina Earnings Conference Call. At this time, all participants are in a listen only mode. After the speaker's presentation ...

Illumina Inc. (NASDAQ: ILMN) released its Q1 2025 earnings presentation on May 8, 2025, reporting revenue of $1.04 billion, representing a slight year-over-year decline of 0.2% in constant ...

Illumina Inc. reported its first-quarter 2025 earnings, revealing an earnings per share (EPS) of $0.97, surpassing analysts’ expectations of $0.94. Despite this positive earnings result, the ...

Anil Agarwal, chairman of the Vedanta Group, recently referred to copper as the “new super metal." There are good reasons for it. Copper is integral to the world’s energy transition and ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

Outside China, revenue is expected to be flat to up 2% in 2025. Illumina now expects between $4.20 and $4.30 in adjusted per-share earnings for the year, down from a previous range of $4.50 to $4. ...

The latest price target for Illumina (NASDAQ:ILMN) was reported by Stephens & Co. on May 20, 2025. The analyst firm set a price target for $105.00 expecting ILMN to rise to within 12 months (a ...